GlobalGov › Germany › Solicitation

Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V i. V. m § 130a Abs. 8 SGB V zum Wirkstoff Crovalimab

AOK Baden-württemberg · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$233,280
Est. Value
Active
Status

Opportunity Overview

Vereinbarung gemäß gemäß § 130c Abs. 1 SGB V i. V. m § 130a Abs. 8 SGB V über die Gewährung von Rabatten für patentgeschützte Arzneimittel mit dem Wirkstoff Crovalimab (PiaSky®)

This Germany Health Services opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyAOK Baden-württemberg
CountryGermany
CategoryHealth Services
Estimated value$233,280
CPV33600000
PublishedSeptember 30, 2026
Procurement stageRequest for Proposal (RFP)
Response dueNot specified / rolling
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 04, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Browse all categories →

Related Opportunities in Germany

Germany – IT services: consulting, software development, Internet and support – AOK BW_OKM 2026 VP
Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zu dem Wirkstoff Concizumab (Alhemo®)
Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung nach § 130a Abs. 8 SGB V zu den Wirkstoffen Wirkstoffen Blutgerinnungsfaktor VII, IX, Simoctocog alfa sowie von Willebrand-Faktor und Blutgerinnungsfaktor VIII in Kombination
Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zu den Wirkstoffen Wirkstoffen Moroctocog alfa (Refacto®) und Nonacog alfa (Benefix®)
Germany – Pharmaceutical products – Vereinbarung gemäß § 130c Abs. 1 SGB V über die Gewährung von Rabatten für patentgeschützte Arzneimittel mit den Wirkstoffen Turoctocog alfa (NovoEight®) und Turoctocog alfa pegol (Esperoct®).
Germany – Pharmaceutical products – Vereinbarung gemäß § 130a Abs. 8 SGB V über die Gewährung von Rabatten für die Arzneimittel mit den Wirkstoffen Blutgerinnungsfaktor VIII (human) sowie von Willebrand-Faktor und Blutgerinnungsfaktor VIII (human) in Kombination
Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zu den Wirkstoffen Damoctocog alfa pegol und Octocog alfa
Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung nach § 130a Abs. 8 SGB V über 9 Präparate zur Behandlung der Hämophilie

See every Germany Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Health Services intelligence report in your inbox

A personalized report on Germany Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.